• June 3-6, 2024
  • San Diego Convention Center, California

Sessions

Loading

Leverna Therapeutics

Thursday, June 06, 2024
Start-Up Stadium Session
CNS/Neurological
Company Description: Leverna Therapeutics is based in Boston area and focuses on drugging RNA regulation in the CNS to flexibly control the target, including up-regulation, down-regulation, function activation & inhibition. Our ASO technology re-directs the fate of RNA, with potentially superior safety. Our lead program L5001 targets the central pathology of ALS disease, applicable to >95% of the patients. A Development Candidate (DC) has been identified and IND filing expected in 2025. Our second program is the first to directly and specifically activate the function of a highly sought-after transcription factor target. All programs exploit novel, druggable RNA processing mechanisms. We are raising Series A to advance the lead program into the clinic and the 2nd program to DC.

Leverna Therapeutics
Company Website: http://www.LevernaTX.com

Company HQ City

Woburn

Company HQ State

MA

Company HQ Country

United States

CEO/Top Company Official

Avery Yan
Primary Speaker
Avery Yan, PhD
Co-Founder, President & CSO/COO
Leverna Therapeutics
Back to Session List

BIO DOUBLE HELIX SPONSORS

Thanks to our sponsors for supporting our mission to drive a revolution to cure patients, protect our climate, and nourish humanity.

Loading

BIO HELIX SPONSORS